CRISPR Therapeutics AG (CRSP) Receivables - Other (2016 - 2024)

CRISPR Therapeutics AG has disclosed Receivables - Other across 9 years of filings, most recently posting $2.1 million for Q4 2024.

• In Q4 2024, Receivables - Other fell 67.69% year-over-year to $2.1 million; the TTM figure through Dec 2024 stood at $2.1 million (down 67.69% YoY), while the FY2024 annual figure was $2.1 million, down 67.69% from the prior year.
• Receivables - Other came in at $2.1 million for Q4 2024 at CRISPR Therapeutics AG, down from $6.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $25.0 million in Q1 2020 to a low of $2.1 million in Q4 2024.
• Average Receivables - Other over 5 years is $14.2 million, with a median of $11.0 million recorded in 2020.
• Year-over-year, Receivables - Other jumped 7688.16% in 2020 and slumped 67.69% in 2024.
• Over 5 years, Receivables - Other stood at $10.7 million in 2020, then declined by 21.5% to $8.4 million in 2021, then surged by 33.33% to $11.2 million in 2022, then plunged by 41.96% to $6.5 million in 2023, then tumbled by 67.69% to $2.1 million in 2024.
• Per Business Quant data, the three most recent Receivables - Other figures were $2.1 million in Q4 2024, $6.5 million in Q4 2023, and $11.2 million in Q4 2022.